| 1 |
29098028 | Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model. | 2017 Nov |
1 |
| 2 |
27198186 | Biology and treatment of cervical adenocarcinoma. | 2016 Apr |
1 |
| 3 |
27272808 | Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion. | 2016 Jun |
1 |
| 4 |
25605928 | Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. | 2015 Feb 3 |
1 |
| 5 |
24864163 | Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. | 2014 |
2 |
| 6 |
25122429 | Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. | 2014 Sep |
1 |
| 7 |
23860535 | Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. | 2013 Aug 6 |
1 |
| 8 |
23925664 | Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. | 2013 |
1 |
| 9 |
22078465 | CYR61 controls p53 and NF-κB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. | 2012 Feb 1 |
1 |
| 10 |
22757735 | Novel antiangiogenic therapies in ovarian cancer. | 2012 Jul |
1 |
| 11 |
21249316 | Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro. | 2011 Apr |
3 |
| 12 |
21805039 | Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. | 2011 Nov |
1 |
| 13 |
21916570 | Bevacizumab in non-small-cell lung cancer: a review. | 2011 Aug |
1 |
| 14 |
20009926 | Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. | 2010 Mar |
1 |
| 15 |
19447868 | Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. | 2009 May 15 |
1 |
| 16 |
19596939 | VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel. | 2009 Jul |
1 |
| 17 |
18606548 | Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. | 2008 Dec |
1 |
| 18 |
17594186 | Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. | 2007 Jul |
1 |
| 19 |
15095298 | Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. | 2004 Jun 20 |
7 |
| 20 |
15330158 | Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines. | 2004 Jul-Aug |
2 |
| 21 |
21533381 | Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients. | 1997 Feb |
1 |